Abstract:The Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 system, a groundbreaking innovation in genetic engineering, has revolutionized our approach to surmounting complex diseases, culminating in CASGEVY™ approved for sickle cell anemia. Derived from a microbial immune defense mechanism, CRISPR/Cas9, characterized as precision, maneuverability and universality in gene editing, has been harnessed as a versatile tool for precisely manipulating DNA in mammals. In the process of applying it to practice, the consecutive exploitation of novel orthologs and variants never ceases. It's conducive to understanding the essentialities of diseases, particularly cancer, which is crucial for diagnosis, prevention, and treatment. CRISPR/Cas9 is used not only to investigate tumorous genes functioning but also to model disparate cancers, providing valuable insights into tumor biology, resistance, and immune evasion. Upon cancer therapy, CRISPR/Cas9 is instrumental in developing individual and precise cancer therapies that can selectively activate or deactivate genes within tumor cells, aiming to cripple tumor growth and invasion and sensitize cancer cells to treatments. Furthermore, it facilitates the development of innovative treatments, enhancing the targeting efficiency of reprogrammed immune cells, exemplified by advancements in CAR-T regimen. Beyond therapy, it is a potent tool for screening susceptible genes, offering the possibility of intervening before the tumor initiative or progresses. However, despite its vast potential, the application of CRISPR/Cas9 in cancer research and therapy is accompanied by significant efficacy, efficiency, technical, and safety considerations. Escalating technology innovations are warranted to address these issues. The CRISPR/Cas9 system is revolutionizing cancer research and treatment, opening up new avenues for advancements in our understanding and management of cancers. The integration of this evolving technology into clinical practice promises a new era of precision oncology, with targeted, personalized, and potentially curative therapies for cancer patients.

Gene editing using CRISPR-Cas9 for the treatment of lung cancer

Development and application of CRISPR/Cas9 technologies in genomic editing.

Gene Editing and Genetic Lung Disease. Basic Research Meets Therapeutic Application

CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer

CRISPR-Cas9-mediated gene therapy in lung cancer

Utilization of TALEN and CRISPR/Cas9 Technologies for Gene Targeting and Modification

CRISPR/Cas9-Mediated Genome Editing in Cancer Therapy

Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment

Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders

Targeted therapies for non-small cell lung cancer based on CRISPR-Cas9 technology

Utilization of TALEN and CRISPR/Cas9 technologies for gene targeting and modification.

Harnessing the evolving CRISPR/Cas9 for precision oncology

Cancer Research Using Crispr/Cas9 Gene Editing Technology

Genome Editing Approaches with CRISPR/Cas9 for Cancer Treatment: Critical Appraisal of Preclinical and Clinical Utility, Challenges, and Future Research

Progress in the application of gene editing technology in cancer treatmentstaking CRISPR as an example

Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies

The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases

CRISPR/Cas9‐mediated genome editing: From basic research to translational medicine

CRISPR-Based Gene Editing: a Modern Approach for Study and Treatment of Cancer

A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing

Targeting Cancer with CRISPR/Cas9-Based Therapy